Zolpidem, eszopiclone, temazepam, and triazolam are gamma-aminobutyric acid type A (GABAA) modulators acting on benzodiazepine recognition sites for the management of insomnia.
May be abused agents.
May impair cognitive abilities and cause anterograde amnesia.
Can impair motor function.
Can precipitate withdrawal symptoms on their discontinuation such as insomnia, delirium, irritability, headache, gastrointestinal symptoms and seizures.
Use of these agents discouraged in individuals with a history of substance abuse or dependence.